The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

Key opinion leaders explores the management of gastrointestinal side effects in patients on osimertinib, focusing on ...

Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, ...

Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, ...

Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including ...

Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due ...

The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...

This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle ...

Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...

Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...